1-800-887-8100
COPAXONE® (glatiramer acetate injection) 40 mg/mL Logo
DOWNLOAD PRESCRIPTION & SERVICE REQUEST FORM (PSR)
MENU
Shared Solutions®
DOWNLOAD PRESCRIPTION & SERVICE REQUEST FORM (PSR)
Copaxone® is the #1 prescribed brand for relapsing MS in the US 1*

Helping patients stay committed to their COPAXONE® therapy

Teva’s Shared Solutions® offers a full range of support services to help your patients stay the course and reach their COPAXONE® treatment goals

Teva-trained nurses

Reliable partners for your patients and your practice

Teva-trained nurses provide your patients with services to help them stay on track, including

Small Change, Big Difference

Teva-trained nurses can help encourage your patients to stay on therapy.

See Services Offered

Personalized communication from Teva’s Shared Solutions® helps to offer patients the support they need throughout their therapy experience

Teva’s Shared Solutions® gives personal attention to COPAXONE® patients — patients receive ongoing contact from the team at Shared Solutions® via email, mail, and phone, so you can be confident that they have support every step of the way.

Teva’s Shared Solutions® PLUS

Teva’s Shared Solutions® PLUS — Compliance and adherence support for the critical first 90 days on COPAXONE®

Teva understands that some patients may be at a higher risk of discontinuing therapy. That's why Teva’s Shared Solutions® PLUS provides extra high-touch support so that you can be reassured that these patients are feeling cared for.

Who can benefit most from Teva’s Shared Solutions® PLUS?

Characteristics that may present barriers to compliance/adherence include

COPAXONE iTracker®

A mobile tool to help patients track their injections

Teva’s Shared Solutions® presents the COPAXONE iTracker® — an app that lets patients manage their injection routines using their Apple or Android mobile devices.

COPAXONE iTracker®

With a customizable, user-friendly interface, the COPAXONE iTracker® allows patients to

  • Record and track injections, injection areas, and site and depth settings
  • Create a 3-times-a-week injection schedule that works for them
    • The COPAXONE iTracker® alerts patients when they forget to record an injection
  • Set injection and prescription refill reminders
  • Connect directly to a Teva’s Shared Solutions® nurse for support
  • Receive daily injection tips
  • Automatically sync data with COPAXONE webTrackerTM

Ask your patients to download COPAXONE iTracker® for their Apple® or Android™ mobile devices from the iTunes® App store or Google Play™ store

App Store icon Google play icon

More tracking tools

Teva’s Shared Solutions® cares about helping your patients stay on track with COPAXONE® that's why patients are offered innovative, interactive injection tracking tools to help them manage their injections and stay compliant.

COPAXONE webTrackerTM

The autoject ®2 for glass syringe helps patients to manage their COPAXONE® injections

  • Patients do not have to see the needle while injecting
  • COPAXONE® therapy is delivered at the touch of a button
  • The autoject®2 for glass syringe can be used with both 20 mg/mL and 40 mg/mL formulations

autoject® 2 for glass syringe
Not actual size.

The autoject®2 for glass syringe is available through Teva’s Shared Solutions® for free with a physician's prescription.

  • Free replacements with prescription
  • Designed for 1,000 injections or 3 years of use, whichever comes first1

Look for the blue plunger

Teva's 3-times-a-week COPAXONE® 40 mg can be identified by the blue plunger.

COPAXONE® 40 mg can be identified by the blue plunger
Not actual size.

Teva’s Shared Solutions® is committed to helping your patients find financial solutions to start and stay on their COPAXONE® treatment
Explore financial solutions
In-home initial injection trainings help support patients' injection experience
Learn more
Explore milestones in the development of COPAXONE® as an enduring option in relapsing MS care.
VIEW OUR TIMELINE

Indication

COPAXONE® (glatiramer acetate injection) is indicated for the treatment of patients with relapsing forms of multiple sclerosis.

 

Important Safety Information

COPAXONE® is contraindicated in patients with known hypersensitivity to glatiramer acetate or mannitol.

Approximately 16% of patients exposed to COPAXONE® 20 mg per mL compared to 4% of those on placebo, and approximately 2% of patients exposed to COPAXONE® 40 mg per mL compared to none on placebo experienced a constellation of symptoms immediately after injection that included at least 2 of the following: flushing, chest pain, palpitations, anxiety, dyspnea, throat constriction, and urticaria. In general, these symptoms have their onset several months after the initiation of treatment, although they may occur earlier, and a given patient may experience 1 or several episodes of these symptoms. Typically, the symptoms were transient and self-limited and did not require treatment; however, there have been reports of patients with similar symptoms who received emergency medical care.

Transient chest pain was noted in 13% of COPAXONE® 20 mg per mL patients compared to 6% of placebo patients, and approximately 2% of COPAXONE® 40 mg per mL patients compared to 1% on placebo. While some episodes of chest pain occurred in the context of the immediate postinjection reaction described above, many did not. The temporal relationship of this chest pain to an injection was not always known. The pain was usually transient, often unassociated with other symptoms, and appeared to have no clinical sequelae. Some patients experienced more than 1 such episode, and episodes usually began at least 1 month after the initiation of treatment.

At injection sites, localized lipoatrophy and, rarely, injection site skin necrosis may occur. Lipoatrophy may occur at various times after treatment onset (sometimes after several months) and is thought to be permanent. There is no known therapy for lipoatrophy.

Because COPAXONE® can modify immune response, it may interfere with immune functions. For example, treatment with COPAXONE® may interfere with recognition of foreign antigens in a way that would undermine the body's tumor surveillance and its defenses against infection. There is no evidence that COPAXONE® does this, but there has not been a systematic evaluation of this risk.

In controlled studies of COPAXONE® 20 mg per mL, the most common adverse reactions with COPAXONE® vs placebo were injection site reactions (ISRs), such as erythema (43% vs 10%); vasodilatation (20% vs 5%); rash (19% vs 11%); dyspnea (14% vs 4%); and chest pain (13% vs 6%).

In a controlled study of COPAXONE® 40 mg per mL, the most common adverse reactions with COPAXONE® vs placebo were ISRs, such as erythema (22% vs 2%).

ISRs were one of the most common adverse reactions leading to discontinuation of COPAXONE®. ISRs, such as erythema, pain, pruritus, mass, edema, hypersensitivity, fibrosis, and atrophy, occurred at a higher rate with COPAXONE® than placebo.

Please see full Prescribing Information for COPAXONE®.

Reference

  1. COPAXONE® (glatiramer acetate injection) prescribing information. Rev. 8/2016. Teva Neuroscience, Inc.

Injections for 3-times-a-week COPAXONE® 40 mg must be at least 48 hours apart.

IMPORTANT SAFETY INFORMATION

COPAXONE® is contraindicated in patients with known hypersensitivity to glatiramer acetate or mannitol.
Approximately 16% of patients exposed to COPAXONE® 20 mg per mL compared to 4% of those on placebo, and approximately 2% of

Indication

COPAXONE® (glatiramer acetate injection) is indicated for the treatment of patients with relapsing forms of multiple sclerosis.

 

Important Safety Information

COPAXONE® is contraindicated in patients with known hypersensitivity to glatiramer acetate or mannitol.

Approximately 16% of patients exposed to COPAXONE® 20 mg per mL compared to 4% of those on placebo, and approximately 2% of patients exposed to COPAXONE® 40 mg per mL compared to none on placebo experienced a constellation of symptoms immediately after injection that included at least 2 of the following: flushing, chest pain, palpitations, anxiety, dyspnea, throat constriction, and urticaria. In general, these symptoms have their onset several months after the initiation of treatment, although they may occur earlier, and a given patient may experience 1 or several episodes of these symptoms. Typically, the symptoms were transient and self-limited and did not require treatment; however, there have been reports of patients with similar symptoms who received emergency medical care.

Transient chest pain was noted in 13% of COPAXONE® 20 mg per mL patients compared to 6% of placebo patients, and approximately 2% of COPAXONE® 40 mg per mL patients compared to 1% on placebo. While some episodes of chest pain occurred in the context of the immediate postinjection reaction described above, many did not. The temporal relationship of this chest pain to an injection was not always known. The pain was usually transient, often unassociated with other symptoms, and appeared to have no clinical sequelae. Some patients experienced more than 1 such episode, and episodes usually began at least 1 month after the initiation of treatment.

At injection sites, localized lipoatrophy and, rarely, injection site skin necrosis may occur. Lipoatrophy may occur at various times after treatment onset (sometimes after several months) and is thought to be permanent. There is no known therapy for lipoatrophy.

Because COPAXONE® can modify immune response, it may interfere with immune functions. For example, treatment with COPAXONE® may interfere with recognition of foreign antigens in a way that would undermine the body's tumor surveillance and its defenses against infection. There is no evidence that COPAXONE® does this, but there has not been a systematic evaluation of this risk.

In controlled studies of COPAXONE® 20 mg per mL, the most common adverse reactions with COPAXONE® vs placebo were injection site reactions (ISRs), such as erythema (43% vs 10%); vasodilatation (20% vs 5%); rash (19% vs 11%); dyspnea (14% vs 4%); and chest pain (13% vs 6%).

In a controlled study of COPAXONE® 40 mg per mL, the most common adverse reactions with COPAXONE® vs placebo were ISRs, such as erythema (22% vs 2%).

ISRs were one of the most common adverse reactions leading to discontinuation of COPAXONE®. ISRs, such as erythema, pain, pruritus, mass, edema, hypersensitivity, fibrosis, and atrophy, occurred at a higher rate with COPAXONE® than placebo.

Please see full Prescribing Information for COPAXONE®.

You are now leaving this website

The website you are about to visit does not belong to Teva Neuroscience, Inc. or follow the same terms of service. Some of these websites may also require a third-party account, subscription, or payment to view.

While we carefully choose which websites we link to, we cannot control any changes or actions made by them. As a result, Teva makes no warranties or representations of any kind as to the accuracy, currency, or completeness of the following site, nor any liability on their behalf.

Continue to site
×